Skip to content
Screener

Zymeworks ZYME Interest Expense

Interest Expense at other companies

Amgen logo
AmgenAMGN
$673M-3.0%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
-$42K-100%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$1.75M+51.6%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$0-100%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$4.62M+12.3%
Royalty Pharma logo
Royalty PharmaRPRX
$93.62M+36.3%

Other financials

Income statement

See full
Revenue$4.6M-90.6%
Operating income-$42.2M-6,158%
Net income-$45.0M-2,043%
EPS (diluted)-$0.62-2,167%

Balance sheet

See full
Cash & equivalents$179.4M+82.6%
Total debt$16.0M-14.3%
Total equity$80.4M-76.0%
Total assets$397.0M-2.8%

Cash flow

See full
Operating cash flow-$31.9M-365%
CapEx$216.0K+1,250%
Free cash flow-$31.9M-376%

Valuation

See full
Market cap$1.7B+83.2%
Enterprise value$1.54B+81.1%
P/S45.8×+38.3×

Profitability

See full
Operating margin-419%-518pp
Net margin-404%-489pp
FCF margin-324.7%-366pp

Returns & leverage

See full
Return on equity-72.3%-117pp
Debt / equity0.2×+0.1×
Current ratio6.3×-1.4×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNonoperatingNet.

The source filing: Zymeworks’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:11 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001937653-26-000047
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Total operating expenses46,77049,40096,296102,123
Loss from operations(42,180)(674)(89,298)(26,287)
Other (expense) income:
Interest income3,2873,4265,9986,850
Interest expense related to sale of future royalties(6,595)(8,661)
Other income (expense), net196(621)316(572)
Total other (expense) income, net(3,112)2,805(2,347)6,278
(Loss) income before income taxes(45,292)2,131(91,645)(20,009)

Item 1. Financial Statements

FAQ

What is Zymeworks's interest expense?
Zymeworks (ZYME) reported interest expense of $3.29M in Q2 2026.
How has Zymeworks's interest expense changed year-over-year?
Zymeworks's interest expense decreased by 4.1% year-over-year, from $3.43M to $3.29M.
What is the long-term trend for Zymeworks's interest expense?
Over 3 years (2022 to 2025), Zymeworks's interest expense has grown at a 54.9% compound annual growth rate (CAGR), from $3.6M to $13.35M.
What does interest expense mean?
Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.

Ask your AI about Zymeworks's interest expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude